Cancer Recurrence vs. A New Primary Cancer

A new spot turns up on imaging in someone with a cancer history. There are two main explanations. They are not variations of one thing.

A recurrence is the original cancer returning after a period when it could not be detected. NCI groups recurrences into three types. Local means in or very near the original site. Regional means in nearby lymph nodes or tissues. Distant means in organs far away. A recurrence keeps its original identity. Colon cancer that reappears in the liver is still colon cancer, and it is treated as colon cancer.

A second primary cancer is a new, unrelated disease. NCI is explicit that this is a different situation from recurrent cancer. The American Cancer Society defines it the same way: a new cancer, which may even arise in the same organ as the first.

On a CT report, both can appear as "a new lesion". The distinction is made in the laboratory.

The first evidence is histology (how the cells look under a microscope). A pathologist examines the tissue. The question is whether the cell type matches the original tumor. Say a tumor in the lung is made of glandular cells that look like colorectal adenocarcinoma. That is behaving like colorectal cancer that has spread. Now say a lung tumor has squamous features, and the first cancer was a colorectal adenocarcinoma. That raises the possibility of an independent lung primary.

Growth pattern matters too. Metastases tend to be well-circumscribed, meaning they have a clear edge. They are often multiple. They sit at the periphery of an organ, following the blood supply. New primaries more often arise from the lining tissue of the organ. Sometimes pre-cancerous changes are visible nearby. That finding argues strongly for a new primary.

Sometimes appearance alone is not enough. Then the lab applies immunohistochemistry (a stain that shows which proteins a cell is making). These stains detect proteins characteristic of particular tissues. The lab chooses a panel to answer the specific question. Familiar examples include TTF-1 for lung origin, CDX2 and CK20 for colorectal, GATA3 for breast and urothelial, and PAX8 for kidney, thyroid and gynaecological tumors.

In breast cancer, hormone receptor and HER2 status add another layer. A recurrence usually keeps the receptor profile of the original tumor, though not always. So a marked mismatch prompts a closer look at whether this is the same disease.

The most decisive evidence is genomic, meaning it comes from the tumor's DNA. Cancers arising from a single original cell carry a shared set of clonal mutations. Those mutations persist as the disease spreads. So the lab sequences the new tumor and compares it against the archived tissue from the original. That answers the question directly. A shared mutation fingerprint indicates the same disease. A completely different driver profile indicates two independent cancers.

This matters most where the two possibilities are genuinely common. A second lung nodule in someone treated for early lung cancer may be a metastasis or a new primary. The two carry very different implications. Comparing driver mutations separates them in a way that imaging and appearance cannot. One tumor may carry an EGFR alteration, for example, and the other a KRAS alteration. This is one reason pathology departments retain original tissue blocks for years. It is also a reason to ask whether your old block was actually pulled and compared.

Timing and treatment history feed into the interpretation as well. A long disease-free interval shifts the assessment. So does a lesion arising within a previously irradiated field. So do known exposures.

• Staging restarts. A second primary is staged from scratch. It may be early-stage and curable, even in someone with a prior advanced cancer.
• Intent changes. A single new primary is often approached surgically with curative intent. Distant recurrence of the original cancer is generally managed as systemic disease.
• Drug choice changes. Therapy is chosen for the tumor's actual identity. Treating a new lung primary with a colorectal regimen, or the reverse, wastes the time in which the right drug would have worked.
• Trial eligibility changes. Trials enrol by tumor type, prior treatment lines and molecular features.

The American Cancer Society groups the causes into three.

The first is previous treatment. Radiation can damage DNA in nearby healthy tissue. Certain chemotherapy classes — alkylating agents, anthracyclines and topoisomerase II inhibitors — raise the risk of leukaemia and myelodysplastic syndrome, a disorder of the bone marrow.

The second is shared risk factors. Smoking, alcohol, excess weight, UV exposure and HPV raised the risk of the first cancer, and they continue to operate.

The third is inherited susceptibility, including syndromes such as BRCA1 and BRCA2. A second primary is often a reason to revisit genetic testing.

• American Cancer Society — Second Cancers in Adults
• NCI — Understanding Cancer Statistics
• NCCN Guidelines for Patients